• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

A History of Aspirin in Modern Disease Prevention

News
Slideshow

Take a look at the evolution of aspirin used in modern disease prevention to gain perspective on how more recent developments may affect your practice.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Metformin May Be Effective Treatment for Atrial Fibrillation in Adults wtih Obesity and Without Diabetes / image credit ©Dieu-Nalio Chery, Michigan Photography

Metformin May Be Effective Treatment for Atrial Fibrillation in Adults wtih Obesity and Without Diabetes

Grace Halsey
November 12th 2025
Article

Research reveals metformin's potential to enhance sinus rhythm stability post-ablation for AF in adults with obesity, independent of weight loss.

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Sydney Jennings
November 13th 2025
Podcast

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

Investigatinal Oral PCSK-9 Inhibitor Reduces LDL-C by 60% in Late Stage HeFH Trial / image courtesy of Baylor college of medicine

Investigational Oral PCSK-9 Inhibitor Reduces LDL-C by 60% in Late Stage HeFH Trial

Grace Halsey
November 10th 2025
Article

Merck's oral PCSK9 inhibitor enlicitide demonstrated antibody-like LDL-C lowering in adutls with HeFH with safety profile similar to placebo in phase 3 trial.

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

Sydney Jennings
September 24th 2025
Podcast

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

CagriSema Reduces SBP by 10.9 mmHg in Post Hoc Analysis of REDEFINE 1 Trial / image credit Subodh Verma, MD, PhD Courtesy of University of Toronto Cardiac Surgery

CagriSema Reduces SBP by 10.9 mmHg in Post Hoc Analysis of REDEFINE 1 Trial

Grace Halsey
November 7th 2025
Article

Nearly 40% of REDEFINE 1 participants taking antihypertensive medications reduced or discontinued their blood pressure drugs during the trial, Novo Nordisk reported.

Wegovy Users More Likely to Reach Key Obesity Treatment Targets, STEP UP Study Finds / image credit: ©Cynthia/AdobeStock

Wegovy Users More Likely to Reach Key Obesity Treatment Targets, STEP UP Study Finds

Sydney Jennings
November 6th 2025
Article

Novo Nordisk’s STEP UP trial shows semaglutide delivers 21% weight loss and reduces key cardiovascular and metabolic risk factors in obesity management.

© 2025 MJH Life Sciences

All rights reserved.